GO:0009117 nucleotide metabolic process: Pan-Cancer Dependency, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009117 nucleotide metabolic process describes all chemical reactions and pathways involving a nucleotide, a nucleoside esterified with phosphate at any hydroxyl group of the glycose moiety, including mono-, di-, tri- and cyclic phosphates.
• Nucleotide metabolism supplies the building blocks of DNA and RNA and the coenzymes and signalling molecules that control cell growth, so it is a pan-cancer metabolic dependency [1,4].
• The pathway is controlled by de novo synthesis, salvage, interconversion and catabolism, and is regulated by nutrient sensors, oncogenic signalling and allosteric feedback [3,7].
• Nucleotide intermediates feed epigenetics by supplying methyl-donor and acetyl-donor coenzymes, linking metabolism directly to chromatin state.
• Colorectal and other tumours show rewired nucleotide metabolic programmes that can be resolved by single-cell, spatial and bulk transcriptomics.
• CRISPR knockout, point-mutation, knock-in and overexpression models, together with CRISPR library screening and bioinformatics, are the core tools for dissecting nucleotide metabolic genes [1,2].
Description
GO:0009117 nucleotide metabolic process is the biological-process ontology term that covers every chemical reaction and pathway involving a nucleotide, defined as a nucleoside esterified with orthophosphate or an oligophosphate at any hydroxyl group of the glycose moiety, including mono-, di- and triphosphates and cyclic nucleotides. In practical terms it spans de novo purine and pyrimidine synthesis, salvage of preformed bases and nucleosides, nucleotide interconversion, and nucleotide catabolism. Because nucleotides are the monomeric precursors of DNA and RNA and the core of coenzymes such as ATP, GTP, NAD and coenzyme A, this process sits at the centre of cellular bioenergetics and information transfer. Researchers study GO:0009117 because proliferating cells must expand nucleotide pools to duplicate their genomes, and because dysregulated nucleotide metabolism is now recognised as a pan-cancer metabolic dependency that offers therapeutic targets [1,4]. The same pathways also shape epigenetics, immune signalling and developmental decisions, making the term relevant far beyond nucleic acid synthesis.
nucleotide metabolic process At A Glance
| GO ID | GO:0009117 |
|---|---|
| GO term | nucleotide metabolic process |
| Ontology | biological_process |
| Synonym | nucleotide metabolism |
| Definition | The chemical reactions and pathways involving a nucleotide, a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic nucleotides (nucleoside cyclic phosphates). |
| Major function | Production, salvage, interconversion and catabolism of nucleotides that supply DNA and RNA precursors, energy carriers and signalling molecules [1,3]. |
| Key subpathways | De novo purine synthesis, de novo pyrimidine synthesis, salvage pathways, nucleotide interconversion, nucleotide catabolism. |
| Representative enzymes | CAD, UMPS, DHODH, IMPDH1/2, GMPS, PFAS, GART, RRM1, RRM2, NME1/2, ADA, HPRT1 [1,2]. |
| Disease relevance | Cancer, inborn errors of purine and pyrimidine metabolism, mitochondrial DNA depletion syndromes, immune and neurological disorders [1,2]. |
What Is GO:0009117?
In our own words, GO:0009117 nucleotide metabolic process is the set of biochemical reactions and pathways that build, interconvert, salvage and break down nucleotides. A nucleotide is a nucleoside (a nitrogenous base linked to a sugar) that carries one or more phosphate groups on a hydroxyl group of the sugar, so the term includes nucleoside monophosphates, diphosphates, triphosphates and cyclic nucleotides such as cAMP and cGMP. The term therefore covers de novo synthesis from small precursors, salvage of bases and nucleosides, phosphorylation and dephosphorylation, and catabolic degradation, as well as the transport steps that feed these reactions [3,8].
Why Is nucleotide metabolic process Important in Cell Biology?
Nucleotide metabolic process matters because every dividing cell must double its nucleotide content before DNA replication, and because nucleotides are not only building blocks but also the currency of energy transfer and the precursors of second messengers and coenzymes [1,7]. Cancer cells frequently reprogramme these pathways to sustain uncontrolled proliferation, which is why nucleotide metabolism is described as a pan-cancer metabolic dependency and why enzymes such as DHODH, IMPDH and ribonucleotide reductase are actively pursued as drug targets [1,4]. At the same time, nucleotide intermediates influence epigenetic marks and immune signalling, so the pathway connects metabolism to gene regulation and host defence.
• Supplies dNTPs and NTPs for DNA replication, repair and RNA transcription.
• Provides ATP and GTP as energy carriers and signalling molecules.
• Generates cyclic nucleotides such as cAMP and cGMP that act as second messengers.
• Feeds coenzymes including NAD, FAD and coenzyme A that support redox and acyl-transfer reactions.
• Is a pan-cancer metabolic dependency and a source of selective anticancer targets [1,4].
• Is rewired in colorectal cancer and can be mapped by single-cell and spatial transcriptomics.
• Links metabolism to epigenetics through methyl-donor and acetyl-donor coenzymes.
• Underlies inborn errors of purine and pyrimidine metabolism with immune and neurological phenotypes.
• Is conserved from diatoms to humans, making model organisms informative for pathway logic.
• Requires careful analytical methods because nucleotide pools are labile and rapidly interconvert.
What Happens During nucleotide metabolic process?
De novo purine and pyrimidine synthesis
In simple terms: Cells build nucleotides from scratch using small molecules such as amino acids, CO2 and PRPP.
De novo synthesis assembles purine and pyrimidine rings from simple precursors. Purine synthesis proceeds through a branched pathway that uses PRPP, glycine, glutamine, aspartate and formyl-THF, with enzymes such as PFAS, GART, IMPDH and GMPS generating IMP and then AMP and GMP. Pyrimidine synthesis begins with CAD, which combines carbamoyl phosphate synthesis and aspartate transcarbamoylase activity, followed by DHODH and UMPS to produce UMP, which is then converted to CTP and dTMP. These pathways are energetically expensive and are tightly coupled to nutrient availability and cell-cycle progression.
Salvage and interconversion
In simple terms: Instead of building from scratch, cells can recycle bases and nucleosides back into nucleotides.
Salvage pathways recover free bases and nucleosides released by nucleic acid turnover, using enzymes such as HPRT1, APRT, ADA and nucleoside kinases. Interconversion reactions then balance the pools of purine and pyrimidine nucleotides, for example through NME1/2, which transfer phosphate between nucleoside di- and triphosphates, and through CTP synthase and dUTPase, which maintain the correct ratios of dNTPs required for faithful DNA replication. Salvage is especially important in tissues with low de novo capacity, such as brain and lymphocytes.
Ribonucleotide reduction and dNTP supply
In simple terms: Ribonucleotides are converted into deoxyribonucleotides, the building blocks of DNA.
Ribonucleotide reductase, composed of RRM1 and RRM2 subunits, catalyses the reduction of NDPs to dNDPs, the rate-limiting step for dNTP production [1,3]. Its activity is cell-cycle regulated and allosterically controlled so that dNTP pools remain balanced; imbalance causes mutagenesis and replication stress. Because proliferating cancer cells depend heavily on this step, RRM1 and RRM2 are established targets and biomarkers in nucleotide metabolic research [1,2].
Nucleotide catabolism and signalling
In simple terms: Nucleotides are also broken down, and some of the products act as signals.
Catabolic enzymes such as ADA, purine nucleoside phosphoryase and ectonucleotidases degrade nucleotides and nucleosides, generating uric acid and other end products. In parallel, cyclic nucleotides such as cAMP and cGMP are synthesised and hydrolysed to transmit hormonal and neuronal signals, and extracellular ATP and adenosine act as danger signals and immune modulators [1,7]. Catabolism therefore both prevents toxic accumulation and produces bioactive mediators.
Compartmentalisation and transport
In simple terms: Nucleotide metabolism happens in different cellular compartments and needs transporters to move intermediates.
De novo purine synthesis occurs in the cytosol, while pyrimidine synthesis is split between cytosol and mitochondria through DHODH, and nucleotide catabolism is partly mitochondrial. Nucleotide sugar and nucleotide transport systems move intermediates across membranes, as shown in diatoms and other organisms. This compartmentalisation allows local control of pools and couples nucleotide metabolism to mitochondrial function and redox balance [3,7].
Key Genes Involved in GO:0009117 nucleotide metabolic process
The following genes encode core enzymes, transporters and regulatory proteins that carry out or control nucleotide metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CAD | Multifunctional enzyme initiating de novo pyrimidine synthesis | Target for pyrimidine pathway inhibition and cancer metabolism studies |
| DHODH | Mitochondrial dihydroorotate dehydrogenase in pyrimidine synthesis | Clinically pursued anticancer and immunomodulatory target [1,3] |
| UMPS | Converts orotate to UMP in pyrimidine synthesis | Biomarker and target in colorectal cancer metabolism |
| IMPDH1 | Rate-limiting enzyme of guanine nucleotide synthesis | Target in leukaemia and antiviral research |
| IMPDH2 | Rate-limiting enzyme of guanine nucleotide synthesis | Pan-cancer dependency and drug target |
| GMPS | Converts XMP to GMP in purine synthesis | Studied in cancer and epigenetic regulation |
| PFAS | Formylglycinamidine ribonucleotide synthase in purine synthesis | Purine pathway dependency in tumours |
| GART | Trifunctional purine synthesis enzyme | Target for purine synthesis inhibition |
| RRM1 | Large subunit of ribonucleotide reductase | Determines dNTP supply and drug response |
| RRM2 | Small subunit of ribonucleotide reductase | Cell-cycle regulated target in cancer [1,2] |
| NME1 | Nucleoside diphosphate kinase | Regulates nucleotide pools and metastasis |
| NME2 | Nucleoside diphosphate kinase | Nucleotide pool balance and signalling |
| HPRT1 | Purine salvage enzyme | Deficiency causes Lesch-Nyhan syndrome |
| ADA | Purine catabolism enzyme | Deficiency causes severe combined immunodeficiency |
| CTPS1 | CTP synthase for pyrimidine nucleotide synthesis | Required for lymphocyte proliferation |
| TYMS | Thymidylate synthase for dTMP synthesis | Classic chemotherapy target |
| ATIC | Bifunctional purine synthesis enzyme | Purine pathway and cancer studies |
How Is nucleotide metabolic process Regulated?
Nucleotide metabolic process is regulated at multiple levels. Nutrient and energy sensors adjust flux according to available carbon, nitrogen and energy, while oncogenic signalling such as MYC and mTOR drives expression of nucleotide synthesis genes to support proliferation [1,4]. Allosteric feedback by end products controls committed steps, for example IMPDH and ribonucleotide reductase are inhibited by downstream nucleotides to keep pools balanced. The pathway is also cell-cycle coupled, with ribonucleotide reductase activity peaking in S phase, and it is integrated with one-carbon metabolism that supplies formyl and methyl groups [3,6]. Because nucleotides participate in epigenetic reactions, changes in their availability can feed back on chromatin and gene expression.
nucleotide metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPRT1 | Lesch-Nyhan syndrome, purine salvage deficiency | HPRT1 knockout cell line and point-mutation knock-in |
| ADA | Severe combined immunodeficiency | ADA knockout and rescue knock-in models |
| IMPDH2 | Cancer cell proliferation and guanine nucleotide dependency | IMPDH2 knockout and inhibitor-treated cancer cells |
| DHODH | Pyrimidine synthesis dependency in cancer and autoimmunity | DHODH knockout and point-mutation models [1,3] |
| RRM2 | dNTP supply, replication stress and drug resistance | RRM2 knockout and overexpression models [1,2] |
Nucleotide metabolism as a pan-cancer dependency
Many tumours reprogramme nucleotide metabolism to sustain rapid proliferation, and this dependence spans multiple cancer types, making the pathway a pan-cancer metabolic dependency. Oncogenic drivers increase flux through de novo synthesis and ribonucleotide reduction, and tumour cells become vulnerable when these enzymes are inhibited [1,4]. In colorectal cancer, integrated single-cell, spatial and bulk RNA-seq analyses have revealed nucleotide metabolic programmes associated with tumour progression and the microenvironment.
Inborn errors of purine and pyrimidine metabolism
Mutations in salvage and catabolic enzymes cause inherited disorders. HPRT1 deficiency leads to Lesch-Nyhan syndrome with neurological and behavioural features, while ADA deficiency causes severe combined immunodeficiency due to toxic nucleotide accumulation in lymphocytes. These disorders illustrate how tightly nucleotide pools must be controlled for normal immune and nervous system function.
Nucleotide metabolism, epigenetics and immune signalling
Nucleotide intermediates supply coenzymes and substrates for DNA and histone methylation and acetylation, so altered nucleotide metabolism can reshape the epigenome. Extracellular nucleotides and adenosine also modulate immune responses, linking this pathway to inflammation and tumour immune evasion [1,7]. This crosstalk makes nucleotide metabolic enzymes attractive for combination therapies that target both metabolism and epigenetic or immune programmes.
From nucleotide metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a nucleotide synthesis gene essential for proliferation? | CRISPR knockout cell line with growth and dNTP pool analysis |
| Does a specific catalytic residue control enzyme activity? | Point-mutation knock-in of the catalytic residue |
| Can a disease-associated variant alter nucleotide flux? | Knock-in of the patient variant with metabolic profiling |
| Where does the enzyme localise in cells? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression drive transformation or drug resistance? | Doxycycline-inducible overexpression cell model |
| Which nucleotide metabolic genes are required in a tumour context? | CRISPR library screening with bioinformatics analysis [1,2] |
How to Study the nucleotide metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS nucleotide profiling | Absolute or relative levels of nucleotides and nucleotide sugars | Testing knockout or drug effects on pools |
| Single-cell RNA-seq | Cell-type-specific expression of nucleotide metabolic genes | Tumour heterogeneity studies |
| Spatial transcriptomics | Spatial distribution of pathway gene expression | Mapping metabolic zones in tumours |
| CRISPR knockout screening | Gene essentiality and fitness effects | Identifying nucleotide metabolic dependencies |
| Isotope tracing | Flux through synthesis, salvage and catabolism | Mechanistic validation of pathway rewiring |
| Western blot and immunostaining | Protein levels and localisation of pathway enzymes | Validating expression and compartmentalisation |
| Enzyme activity assay | Catalytic activity of specific nucleotide enzymes | Characterising point mutations |
| Bioinformatics pathway analysis | Enrichment and network analysis of nucleotide metabolism | Prioritising targets from omics data |
Nucleotide pool quantification
Accurate measurement of nucleotide pools requires rapid quenching and extraction because nucleotides interconvert during sample handling. LC-MS and HPLC methods can quantify mono-, di- and triphosphates and nucleotide sugars, and are used to test how genetic perturbations change flux.
Transcriptomic and spatial mapping
RNA-seq, single-cell RNA-seq and spatial transcriptomics reveal which nucleotide metabolic genes are expressed in specific cell types and tumour regions. Integrating these datasets with bulk RNA-seq helps identify pathway programmes associated with disease progression.
Functional genomics and CRISPR screening
CRISPR knockout and CRISPR library screening identify genes required for proliferation and survival under defined metabolic conditions. Bioinformatics analysis of screen results ranks nucleotide metabolic dependencies and predicts combination vulnerabilities [1,2].
Metabolic flux and isotope tracing
Stable-isotope tracing with labelled glucose, glutamine or nucleosides measures flux through de novo synthesis, salvage and catabolism. These experiments connect genotype to pathway activity and are essential for validating mechanism [3,4].
How CRISPR Can Be Used to Study GO:0009117 nucleotide metabolic process
Knockout
CRISPR knockout of nucleotide metabolic genes such as IMPDH2, DHODH or RRM2 is used to test whether the enzyme is required for proliferation and to measure consequent changes in nucleotide pools. Knockout models also reveal compensatory salvage or de novo pathway use, which is important for anticipating drug resistance [1,3].
Point Mutation
Point-mutation knock-in can model disease-associated variants or catalytically dead enzymes, allowing researchers to separate catalytic activity from scaffolding functions. Such models are valuable for testing whether a specific residue controls allosteric regulation or substrate specificity.
Knock-in
Knock-in of tags, reporters or patient variants enables localisation, interaction and functional studies of nucleotide metabolic enzymes in a native genomic context. Tagged knock-in lines are particularly useful for imaging and proteomic analysis of labile pathway complexes.
Overexpression
Overexpression models test whether increased nucleotide metabolic flux drives transformation, drug resistance or altered epigenetic state [1,6]. Inducible overexpression allows dose- and time-controlled experiments that avoid adaptation artefacts.
How EDITGENE Supports nucleotide metabolic process Research
Researchers studying nucleotide metabolic process-related genes often need to determine whether a candidate gene is causally involved in proliferation, metabolic flux or disease phenotypes, and CRISPR-based cell models provide the most direct way to test causality. EDITGENE supports this work with validated knockout, point-mutation, knock-in and overexpression cell lines, together with CRISPR library screening and bioinformatics services tailored to nucleotide metabolism.
Contact EDITGENE today to design your custom CRISPR model for nucleotide metabolic process research.
Frequently Asked Questions About nucleotide metabolic process
What is nucleotide metabolic process GO:0009117?
GO:0009117 nucleotide metabolic process is the biological-process term for all reactions and pathways involving a nucleotide, a nucleoside esterified with phosphate at a sugar hydroxyl group, including mono-, di-, tri- and cyclic phosphates.
What genes are involved in nucleotide metabolic process?
Core genes include CAD, DHODH, UMPS, IMPDH1, IMPDH2, GMPS, PFAS, GART, RRM1, RRM2, NME1, NME2, HPRT1, ADA, CTPS1, TYMS and ATIC [1,2,3].
Why is nucleotide metabolism important in cancer?
Many tumours depend on increased nucleotide synthesis and salvage to support proliferation, making the pathway a pan-cancer metabolic dependency and a source of therapeutic targets [1,4].
What are the main steps of nucleotide metabolism?
The main steps are de novo purine and pyrimidine synthesis, salvage of bases and nucleosides, interconversion, ribonucleotide reduction to dNTPs, and catabolism.
How is nucleotide metabolism regulated?
It is regulated by nutrient and energy sensors, oncogenic signalling, allosteric feedback by end products and cell-cycle control of enzymes such as ribonucleotide reductase [1,3,4].
What diseases are linked to nucleotide metabolic process?
Diseases include cancer, Lesch-Nyhan syndrome from HPRT1 deficiency, severe combined immunodeficiency from ADA deficiency, and other inborn errors of purine and pyrimidine metabolism [1,3].
How do you measure nucleotide metabolism in the lab?
Common methods include LC-MS nucleotide profiling, isotope tracing, enzyme activity assays and transcriptomic or spatial mapping of pathway genes [2,3,5].
Can CRISPR be used to study nucleotide metabolic genes?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models, plus CRISPR library screening, are widely used to test the function and essentiality of nucleotide metabolic genes [1,2].
What is the role of nucleotide metabolism in epigenetics?
Nucleotide intermediates supply coenzymes and substrates for DNA and histone modifications, linking metabolic flux to chromatin state and gene expression.
Which enzymes are rate-limiting in nucleotide metabolism?
Ribonucleotide reductase, IMPDH and DHODH are key controlled steps in dNTP supply, guanine nucleotide synthesis and pyrimidine synthesis, respectively [1,3].
Conclusion
GO:0009117 nucleotide metabolic process is a central biological process that supplies DNA and RNA precursors, energy carriers, coenzymes and signalling molecules, and its dysregulation is a hallmark of cancer and inherited metabolic disease [1,3,4]. Understanding its de novo, salvage, interconversion and catabolic arms requires integrated genetic, biochemical and computational approaches [2,5]. CRISPR-based cell models combined with CRISPR library screening and bioinformatics provide a rigorous route to assign causality to nucleotide metabolic genes and to identify new therapeutic opportunities [1,2].
References
- 1. Mullen NJ et al.. 2023. Nucleotide metabolism: a pan-cancer metabolic dependency.. Nat Rev Cancer 23(5):275-294 PMID: 36973407
- 2. Zhao S et al.. 2024. Targeting nucleotide metabolic pathways in colorectal cancer by integrating scRNA-seq, spatial transcriptome, and bulk RNA-seq data.. Funct Integr Genomics 24(2):72 PMID: 38594466
- 3. Lane AN et al.. 2015. Regulation of mammalian nucleotide metabolism and biosynthesis.. Nucleic Acids Res 43(4):2466-85 PMID: 25628363
- 4. Vander Heiden MG et al.. 2017. Understanding the Intersections between Metabolism and Cancer Biology.. Cell 168(4):657-669 PMID: 28187287
- 5. Braasch K et al.. 2015. Evaluation of Quenching and Extraction Methods for Nucleotide/Nucleotide Sugar Analysis.. Methods Mol Biol 1321:361-72 PMID: 26082234
- 6. Suganuma T et al.. 2021. Nucleotide Metabolism Behind Epigenetics.. Front Endocrinol (Lausanne) 12:731648 PMID: 34526971
- 7. Veech RL et al.. 2019. The "great" controlling nucleotide coenzymes.. IUBMB Life 71(5):565-579 PMID: 30624851
- 8. Gruber A et al.. 2019. Nucleotide Transport and Metabolism in Diatoms.. Biomolecules 9(12) PMID: 31766535
